Although our original founder, A.P. John, Sr., and his successor and son, A.P. John, Jr., have passed on, we still aim to keep our organization viable to help cancer patients around the world lead lives of enhanced quality through the use of Controlled Amino Acid Therapy (CAAT); to learn more about how various types of cancer cells come into existence, subsist, and die; and to obtain further evidence of the efficacy of our approach. Our goal is to perform a large, scientifically conducted clinical study of the CAAT protocol so that it will receive FDA approval, making it available for the benefit of a greater number of cancer patients. The great advantages of this therapy is that it is nontoxic and helps the body fight cancer using its own mechanisms, has no side effects, and is considerably less expensive than almost any of the standard anti-cancer treatments. It can also be used in conjunction with the standard treatments to enhance their anti-cancer effects and to lessen their side effects.
A Little History
Molecular biologist and cancer scientist, Angelo P. John, Sr., has had a lifelong passion for the study of biochemistry and a devotion to cancer research. It began when he was a child and continued through his college education and adult life.
John founded the A. P. John Institute for Cancer Research in 1978. In previous years, he worked in cancer research with C. Chester Stock, Ph.D., during the latter's tenure as Scientific Director at the Sloan-Kettering Institute for Cancer Research in New York City and Director of the Institute's Walker Laboratory in Rye, New York. He also operated his own research laboratory for more than 18 years. He spent 45 years researching, pioneering, and validating some of the most advanced clinically proven protocols for the treatment of cancer.
In 1961, John published his first anti-cancer diet and nutritional book titled Diaitis: Anti-Cancer Nutrients in Cancer Prevention and Cure. In it, he outlines his theories about the prevention, causality, and treatment of cancer. As far back as 1969, John developed his first two protocols for the treatment of cancer, one called Intra-Tumor Therapy and the other, Ischemia Reperfusion Tumor Therapy. His involvement in Intra-Tumor Therapy began with a cancer study with biologist Robert Holman of Mifflinburg, Pennsylvania. The research proved that Intra-Tumor Therapy cured cancers in laboratory animals. The therapy involves injecting chemicals such as hydrogen peroxide and acetic acid directly into a tumor, which causes it to totally disappear. John's patented Ischemia Reperfusion Tumor Therapy involves inserting a catheter containing a balloon into an artery feeding a tumor. Every half-hour the balloon is either inflated or deflated. During that process of occlusion and reperfusion, the cancer cells undergo a series of chemical reactions that cause them to produce toxic free radicals and self-destruct. [footnote: The results of this research have, unfortunately, been lost.]
Most notably, John developed an integrative biological protocol for the treatment of cancer. His protocol, CAAT is an amino acid and carbohydrate-deprivation cancer therapy, administered to the patient for approximately 6 to 9 months. It strategically and scientifically utilizes the chemical reactions and interactions among amino acids, foods, and nutritional supplements to alter or impair the development of cancer cells. CAAT achieves this goal by interfering and blocking the five basic requirements of cell formation: structure, energy, blood vessels, growth hormones, and functions. It works synergistically with chemotherapy and/or radiation and has also been proven effective alone.
John routinely appeared as a guest on The Helen Larson Talk Show (on cable TV Channel 27) throughout Westchester County, New York, and FairfieldCounty, Connecticut. He was a guest on numerous radio talk shows across the United States. He spoke at the prestigious Wainwright House in Rye, New York; SHARE, Self-Help for Women with Breast or Ovarian Cancer, in New York City; and local clubs throughout the New York Tri-State area. He also presented papers and posters at several medical conferences including the April 2002 conference sponsored by the Harvard School of Medicine; the July 2002 conference at the American Institute for Cancer Research in Washington, D.C.; and the 2003 Comprehensive Cancer Care Conference on Integrating Complementary and Alternative Therapies, jointly sponsored by National Center for Complementary and Alternative Medicine (NCCAM) and the National Cancer Institute (NCI).